Concepedia

Karl Hsu

KH

Statistics

Publications

22

Citations

1.5K

H-Index

18

Active since

1992

Affiliations

Dana-Farber Cancer Institute(Current)

Sanofi (United States)

Memorial Sloan Kettering Cancer Center

Huntsman Cancer Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

Karl Hsu is an author at Dana-Farber Cancer Institute specializing in medicine, life sciences, and cancer pharmacology.

Publications per year

1992–2023

22

Publications

22

Interplay of Pu.1 and Gata1 Determines Myelo-Erythroid Progenitor Cell Fate in Zebrafish

Jennifer Rhodes, Andreas T. Hagen, Karl Hsu et al. · Developmental Cell · 2005 · 362 citations · Full text

Life Sciences, Developmental Biology, Molecular Biology +7

The pu.1 promoter drives myeloid gene expression in zebrafish

Karl Hsu, David Traver, Jeffery L. Kutok et al. · Blood · 2004 · 140 citations · Full text

Life Sciences, Genetics, Molecular Biology +12

A Phase I Pharmacokinetic and Pharmacodynamic Study of Dalotuzumab (MK-0646), an Anti-Insulin-like Growth Factor-1 Receptor Monoclonal Antibody, in Patients with Advanced Solid Tumors

Francesco Atzori, Josep Tabernero, Andrés Cervantes et al. · Clinical Cancer Research · 2011 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17

Knockdown of Zebrafish Fancd2 Causes Developmental Abnormalities via p53-Dependent Apoptosis

Ting Xi Liu, Niall G. Howlett, Min Deng et al. · Developmental Cell · 2003 · 115 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Phase I trial of isatuximab monotherapy in the treatment of refractory multiple myeloma

Thomas G. Martin, Stephen A. Strickland, Martha Glenn et al. · Blood Cancer Journal · 2019 · 107 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

1–5 of 22